Table S1. Top 50 Prescribed Medications in All Patients Supported by ECMO and Supporting Pharmacokinetics and Pharmacodynamics Literature (N=254)

Medications *(% Children Exposed)*	**Study**	**Population Studied*** *(Number of Subjects and Age)*	**Study Design**	**Dosing Guidance** *(for Normal SCR Values)*
Heparin (97%)	Peverini et al. (1) Green et al. (2) Nankervis et al. (3) Bembea et al. (4) Green et al. (5) Moynihan et al. (6) Anton-Martin et al. (7) O'Meara et al. (8) Bingham et al. (9) Kessel et al. (10) Irby et al. (11) Baird et al. (12) Liveris et al. (13) Reed et al. (14) Maul et al. (15) Mehta et al. (16)	(1) 58 infants** (2) 5 neonates (1-7d) (3) 12 neonates** (4) 34 children (median 10 days, IQR 2d-10y) (5) 9 infants (≤7d-120d) (6) 31 children (median 17d, IQR 2d-764d) (7) 2 groups of 36 children (0-158m and 0-203m) (8) 20 children (1d-17y) (9) 35 children (median 39d, IQR 7.5d-392.5d) (10) 18 children (1d-17y) (11) 62 patients (0y-20.7y) (12) 604 children (median 3d, IQR 1-52d) (13) 17 children (1d-13.9y) (14) 29 children (median 2m) (15) 47 children (0-18y)	Retrospective population PK (1) Retrospective PK (2) Prospective PD (3-5) Retrospective PD (6-15) In vitro (16)	Yes, but not readily accessible (1) No (2-16)
Morphine (92%)	Peters et al. (17) Geiduschek et al. (18) Peters et al. (19) Krekels et al. (20) Dagan et al. (21) Michel et al. (22) Dagan et al. (23) Hartan et al. (24) Mehta et al. (16) Nasr et al. (25) Raffaeli et al. (26) Bhatt-Meht et al. (27)	(17) 14 neonates (<7d) (18) 11 neonates (0-9d) (19) 14 neonates (<7d) (20) 30 neonates (0-26d) (21) 7 infants (1d-12m) (22) 17 infants (0-3.3m)	Prospective population PK (17-20) Prospective PK (21) Prospective PD (22) In vitro (16, 23-27)	No (16-27)
Midazolam (86%)	Ahsman et al. (28) Mulla et al. (29) Mulla et al. (30) Michel et al. (22) Hartan et al. (24) Nasr et al. (25) Raffaeli et al. (26) Mulla et al. (31)	(28) 20 neonates (0-6d) (29) 20 neonates (0-18d) (30) 20 neonates (0-18d) (22) 17 infants (0-3.3m)	Prospective population PK (28, 29) Prospective PK/PD (30) Prospective PD (22) In vitro (24-26, 31)	(28) 0.3 mg/kg/h for 6h and 0.15 mg/kg/h thereafter (29) 0.35 mg/kg/h for 6h and 0.05 mcg/kg/h thereafter No (22, 24-26, 29, 31)
Furosemide (83%)	Van der Vorst et al. (32) Van der Vorst et al. (33)	(32) 31 neonates (0-16d) (33) 7 neonates (0-136d)	(32) Retrospective PD (33) Prospective PK/PD	No (32, 33)

Vecuronium (80%)				
Vancomycin (67%)	Cies et al. (34) Moffett et al. (35) Mulla et al. (36) Amaker et al. (37) Buck et al. (38) Hoie et al. (39) Ashman et al. (40) Zylbersztajn et al. (41) Lonabaugh et al. (42) Dagan et al. (23) Mehta et al. (16) Lemaitre et al. (43)	(34) 12 neonates (0-28d) (35) 93 children (median 0.6y, IQR 0.07y-6.7y) (36) 45 patients (0-61.5y) (37) 12 neonates (0-6d) (38) 15 neonates (mean 12.7d ± 5.1) (39) 6 neonates (1-4d) (40) 1 neonate** (41) 40 children (1m-14y) (42) 28 children (0-11y)	Prospective population PK (34) Retrospective population PK (35) Retrospective and prospective population PK (36) Prospective PK/PD (37-39) Prospective PK (40) Retrospective PK/PD (41, 42) In vitro (16, 23, 43)	(34) 10-12.5 mg/kg every 8h; 12.5-20 mg/kg every 12h or continuous infusion of 20-30 mg/kg/24h (35) 25-30 mg/kg every 12-24h (36) 10-20 mg/kg every 6-8h based on age (37) 20 mg/kg every 24h (39) 20 mg/kg every 18h (41) 10 mg/kg every 6h (42) 15 mg/kg every 12h No (16, 23, 38, 40, 43)
Dopamine (61%)	Mehta et al. (16)		In vitro (16)	No (16)
Cefazolin (57%)	Mehta et al. (16) Wildschut et al. (44)		In vitro (16, 44)	No (16, 44)
Cefepime (55%)	Zuppa et al. (45)	(45) 17 children (1.3m-22.2m)	Prospective population PK (45)	No (45)
Milrinone (45%)				
Fentanyl (44%)	Arnold et al. (46) Leuschen et al. (47) Arnold et al. (48) Hartan et al. (24) Mehta et al. (16) Nasr et al. (25) Raffaeli et al. (26) Preston et al. (49)	(46) 8 neonates (1-14d) (47) 12 infants (1-42d) (48) 37 neonates (5 neonates with PK samples)**	Prospective PK/PD (46, 47) Retrospective and prospective PK/PD (48) In vitro (16, 24-26, 49)	(47) Bolus of 5-10 μg/kg and continuous infusion of 1-5 μg/kg/h thereafter No (16, 24-26, 46-49)
Hydrocortisone (43%)	Mehta et al. (16)		In vitro (16)	No (16)
Pantoprazole (40%)				
Epinephrine (35%)	Mehta et al. (16)		In vitro (16)	No (16)
Acetaminophen (33%)	Wildschut et al. (44)		In vitro (44)	No (44)
Chlorothiazide (33%)				
Ampicillin (31%)	Mehta et al. (16)		In vitro (16)	No (16)
Dexmedetomidine (28%)	Nasr et al. (25)		In vitro (25)	No (25)
Ranitidine (25%)	Wells et al. (50) Crill et al. (51)	(50) 13 neonates (includes 12 neonates < 4d) (51) 13 neonates (1-7d)	Prospective PK/PD (50) Retrospective PD (51)	(50) Bolus of 2 mg/kg and continuous infusion of 2 mg/kg/24h No (51)

Gentamicin (24%)	Dodge et al. (52) Cohen et al. (53) Moffett et al. (54) Southgate et al. (55) Munzenberger et al. (56) Bhatt-Mehta et al. (57) Dagan et al. (23)	(52) 11 neonates (PCA 37-42w) (53) 18 neonates (2-8d) (54) 37 infants (median of 0.17m – IQR 0.12-0.82) (53) (55) 10 infants** (56) 15 neonates** (57) 29 neonates**	Prospective population PK (52, 53) Retrospective population PK (54) Prospective PK/PD (55, 56) Retrospective PK/PD (57) In vitro (23)	(52) Loading dose of 4.3 mg/kg and 3.7 mg/kg every 18-24h thereafter (53) 3 mg/kg every 18h if BW <3.5 kg and 2.5 mg/kg every 18h if BW >3.5kg (54) 4-5 mg/kg every 24h (55) 2.5 mg/kg followed by TDM (57) 2.5 mg/kg every 18h No (23, 56)
Hydromorphone (23%)	Reiter (58)	(58) 12 children (0-17y)	Retrospective PD study (58)	No (58)
Albuterol (22%)				
Ketamine (20%)				
Nicardipine (17%)	Liviskie et al. (59) McBride et al. (60) Tobias et al. (61)	(59) 8 neonates (median GA 36.5 weeks - IQR: 35.3-38) (60) 1 neonate (6d) (61) 1 children (19m)	Retrospective PD (59) Case report (60, 61)	(60) 0.5 µg/kg/min titrated to effect (61) 5 µg/kg/min titrated to effect No (59)
Pentobarbital (17%)				
Hydralazine (16%)	Martin et al. (62)	(62) 23 infants**	Prospective PD (62)	No (62)
Dexamethasone (15%)				
Piperacillin-Tazobactam (15%)				
Alprostadil (14%)	Stone et al. (63)	(63) 1 neonate**	Case report (63)	No (63)
Aminocaproic Acid (14%)	Horwitz et al. (64) Wilson et al. (65) Downard et al. (66)	(64) 13 neonates** (65) 42 children** (66) 298 children (4 groups with medians of 1d, 70d, 2y and 19y)	Prospective PD (64) Retrospective PD (65, 66)	No (64-66)
Levetiracetam (14%)				
Methylprednisolone (13%)				
Lorazepam (12%)	Bhatt-Meht et al. (27) Mulla et al. (31)		In vitro (27, 31)	No (27, 31)
Phenobarbital (12%)	Pokorna et al. (67) Elliott et al. (68) Dagan et al. (23) Mehta et al. (16)	(67) 7 neonates and 9 infants** (68) 1 neonate (2d)	Retrospective population PK (67) Case report (68) In vitro (16, 23)	(67) 15 mg/kg bolus and 4 mg/kg daily thereafter No (16, 23, 68)
Vasopressin (12%)				
Diphenhydramine (11%)				
Lidocaine (11%)				
Insulin (10%)				
Norepinephrine (10%)				

Acetazolamide (9%)				
Acyclovir (9%)	Cies et al. (69)	(69) 1 neonate (14d)	Case report (69)	No (69)
Docusate Sodium (9%)				
Rocuronium (9%)				
Sennosides (9%)				
Treprostinil (9%)				
Amiodarone (7%)	Kendrick et al. (70)	(70) 1 infant (4d)	Case report (70)	(70) 20 µg/kg/min as a continuous infusion
Bumetanide (7%)	Wells et al. (71)	(71) 11 neonates (1-7d)	Prospective PK/PD (71)	No (71)
Cisatracurium (7%)				
Fluconazole (7%)	Watt et al. (72) Watt et al. (73) Minette et al. (74) Watt et al. (75)	(72) 40 children (1-6498d) (73) 10 infants (1-113d) (74) 1 neonate (16d)	Prospective population PK study (72) Prospective PK/PD study (73) Case report (74) In vitro (75)	(72) loading dose of 12 mg/kg and 6 mg/kg daily thereafter (prophylaxis); loading dose of 35 mg/kg and 12 mg/kg daily thereafter (treatment) (73) 25 mg/kg weekly (prophylaxis) No (74, 75)
Meropenem (7%)	Cies et al. (76) Cies et al. (77) Di Nardo et al. (78) Wildschut et al. (44)	(76) 1 infant (8m) (77) 1 neonate (10d) (78) 2 infants (175d ± 10d)	Case report (76-78) In vitro study (44)	(76) Loading dose of 40 mg/kg and continuous infusion of 200 mg/kg/24h thereafter (77) Loading dose of 40 mg/kg and continuous infusion of 240 mg/kg/24h thereafter No (44, 78)

BW: birth weight, GA: gestational age, PCA: postconceptual age, PD: pharmacodynamics, PK: pharmacokinetics, SCR: serum creatinine, TDM: Therapeutic Drug Monitoring

**When applicable; age range otherwise specified; age in days (d), months (m) or years(y)*

***Age not specified*

1. Peverini RL, Sale M, Rhine WD, et al. Anticoagulation therapy advisor: a decision-support system for heparin therapy during ECMO. Proc Annu Symp Comput Appl Med Care 1992:567-571.
2. Green TP, Isham-Schopf B, Irmiter RJ, et al. Inactivation of heparin during extracorporeal circulation in infants. Clin Pharmacol Ther 1990;48(2):148-154.
3. Nankervis CA, Preston TJ, Dysart KC, et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. Asaio j 2007;53(1):111-114.
4. Bembea MM, Schwartz JM, Shah N, et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. Asaio j 2013;59(1):63-68.
5. Green TP, Isham-Schopf B, Steinhorn RH, et al. Whole blood activated clotting time in infants during extracorporeal membrane oxygenation. Crit Care Med 1990;18(5):494-498.
6. Moynihan K, Johnson K, Straney L, et al. Coagulation monitoring correlation with heparin dose in pediatric extracorporeal life support. Perfusion 2017;32(8):675-685.
7. Anton-Martin P, Journeycake J, Modem V, et al. Coagulation Profile Is Not a Predictor of Acute Cerebrovascular Events in Pediatric Extracorporeal Membrane Oxygenation Patients. Asaio j 2017;63(6):793-801.
8. O'Meara LC, Alten JA, Goldberg KG, et al. Anti-xa directed protocol for anticoagulation management in children supported with extracorporeal membrane oxygenation. Asaio j 2015;61(3):339-344.
9. Bingham KR, Riley JB, Schears GJ. Anticoagulation Management during First Five Days of Infant-Pediatric Extracorporeal Life Support. J Extra Corpor Technol 2018;50(1):30-37.
10. Kessel AD, Kline M, Zinger M, et al. The Impact and Statistical Analysis of a Multifaceted Anticoagulation Strategy in Children Supported on ECMO: Performance and Pitfalls. J Intensive Care Med 2017;32(1):59-67.
11. Irby K, Swearingen C, Byrnes J, et al. Unfractionated heparin activity measured by anti-factor Xa levels is associated with the need for extracorporeal membrane oxygenation circuit/membrane oxygenator change: a retrospective pediatric study. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2014;15(4):e175-182.
12. Baird CW, Zurakowski D, Robinson B, et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. Ann Thorac Surg 2007;83(3):912-919; discussion 919-920.
13. Liveris A, Bello RA, Friedmann P, et al. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2014;15(2):e72-79.
14. Reed RC, Rutledge JC. Laboratory and clinical predictors of thrombosis and hemorrhage in 29 pediatric extracorporeal membrane oxygenation nonsurvivors. Pediatr Dev Pathol 2010;13(5):385-392.
15. Maul TM, Wolff EL, Kuch BA, et al. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation. Pediatric critical care

medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2012;13(6):e363-371.
16. Mehta NM, Halwick DR, Dodson BL, et al. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med 2007;33(6):1018-1024.
17. Peters JW, Anderson BJ, Simons SH, et al. Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. Intensive Care Med 2005;31(2):257-263.
18. Geiduschek JM, Lynn AM, Bratton SL, et al. Morphine pharmacokinetics during continuous infusion of morphine sulfate for infants receiving extracorporeal membrane oxygenation. Crit Care Med 1997;25(2):360-364.
19. Peters JW, Anderson BJ, Simons SH, et al. Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates. Clin Pharmacokinet 2006;45(7):705-714.
20. Krekels EH, DeJongh J, van Lingen RA, et al. Predictive Performance of a Recently Developed Population Pharmacokinetic Model for Morphine and its Metabolites in New Datasets of (Preterm) Neonates, Infants and Children. Clin Pharmacokinet 2011;50(1):51-63.
21. Dagan O, Klein J, Bohn D, et al. Effects of extracorporeal membrane oxygenation on morphine pharmacokinetics in infants. Crit Care Med 1994;22(7):1099-1101.
22. Michel J, Hofbeck M, Gerbig I, et al. Nurse-driven analgesia and sedation in pediatric patients with univentricular hearts requiring extracorporeal life support after first-stage palliation surgery: A pilot study. Paediatric anaesthesia 2017;27(12):1261-1270.
23. Dagan O, Klein J, Gruenwald C, et al. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 1993;15(4):263-266.
24. Harthan AA, Buckley KW, Heger ML, et al. Medication adsorption into contemporary extracorporeal membrane oxygenator circuits. J Pediatr Pharmacol Ther 2014;19(4):288-295.
25. Nasr VG, Meserve J, Pereira LM, et al. Sedative and Analgesic Drug Sequestration After a Single Bolus Injection in an Ex Vivo Extracorporeal Membrane Oxygenation Infant Circuit. Asaio j 2019;65(2):187-191.
26. Raffaeli G, Allegaert K, Koch B, et al. In Vitro Adsorption of Analgosedative Drugs in New Extracorporeal Membrane Oxygenation Circuits. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2018;19(5):e251-e258.
27. Bhatt-Meht V, Annich G. Sedative clearance during extracorporeal membrane oxygenation. Perfusion 2005;20(6):309-315.
28. Ahsman MJ, Hanekamp M, Wildschut ED, et al. Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Clin Pharmacokinet 2010;49(6):407-419.

29. Mulla H, McCormack P, Lawson G, et al. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. Anesthesiology 2003;99(2):275-282.
30. Mulla H, Lawson G, Peek GJ, et al. Plasma concentrations of midazolam in neonates receiving extracorporeal membrane oxygenation. Asaio j 2003;49(1):41-47.
31. Mulla H, Lawson G, von Anrep C, et al. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion 2000;15(1):21-26.
32. van der Vorst MM, Wildschut E, Houmes RJ, et al. Evaluation of furosemide regimens in neonates treated with extracorporeal membrane oxygenation. Crit Care 2006;10(6):R168.
33. van der Vorst MM, den Hartigh J, Wildschut E, et al. An exploratory study with an adaptive continuous intravenous furosemide regimen in neonates treated with extracorporeal membrane oxygenation. Crit Care 2007;11(5):R111.
34. Cies JJ, Moore WS, 2nd, Nichols K, et al. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2017;18(10):977-985.
35. Moffett BS, Morris J, Galati M, et al. Population Pharmacokinetics of Vancomycin in Pediatric Extracorporeal Membrane Oxygenation. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2018.
36. Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol 2005;60(3):265-275.
37. Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrobial agents and chemotherapy 1996;40(5):1139-1142.
38. Buck ML. Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1998;18(5):1082-1086.
39. Hoie EB, Swigart SA, Leuschen MP, et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin Pharm 1990;9(9):711-715.
40. Ahsman MJ, Wildschut ED, Tibboel D, et al. Microanalysis of beta-lactam antibiotics and vancomycin in plasma for pharmacokinetic studies in neonates. Antimicrobial agents and chemotherapy 2009;53(1):75-80.
41. Zylbersztajn BL, Izquierdo G, Santana RC, et al. Therapeutic Drug Monitoring of Vancomycin in Pediatric Patients With Extracorporeal Membrane Oxygenation Support. J Pediatr Pharmacol Ther 2018;23(4):305-310.
42. Lonabaugh KP, Lunsford KJ, Fang GY, et al. Vancomycin Dosing in Pediatric Extracorporeal Membrane Oxygenation: Potential Impacts of New Technologies. J Pediatr Pharmacol Ther 2017;22(5):358-363.
43. Lemaitre F, Hasni N, Leprince P, et al. Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood. Crit Care 2015;19:40.

44. Wildschut ED, Ahsman MJ, Allegaert K, et al. Determinants of drug absorption in different ECMO circuits. Intensive Care Med 2010;36(12):2109-2116.
45. Zuppa AF, Zane NR, Moorthy G, et al. A Population Pharmacokinetic Analysis to Study the Effect of Extracorporeal Membrane Oxygenation on Cefepime Disposition in Children. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2019;20(1):62-70.
46. Arnold JH, Truog RD, Scavone JM, et al. Changes in the pharmacodynamic response to fentanyl in neonates during continuous infusion. The Journal of pediatrics 1991;119(4):639-643.
47. Leuschen MP, Willett LD, Hoie EB, et al. Plasma fentanyl levels in infants undergoing extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 1993;105(5):885-891.
48. Arnold JH, Truog RD, Orav EJ, et al. Tolerance and dependence in neonates sedated with fentanyl during extracorporeal membrane oxygenation. Anesthesiology 1990;73(6):1136-1140.
49. Preston TJ, Hodge AB, Riley JB, et al. In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit. J Extra Corpor Technol 2007;39(4):234-237.
50. Wells TG, Heulitt MJ, Taylor BJ, et al. Pharmacokinetics and pharmacodynamics of ranitidine in neonates treated with extracorporeal membrane oxygenation. Journal of clinical pharmacology 1998;38(5):402-407.
51. Crill CM, Bugnitz MC, Hak EB. Evaluation of gastric pH and guaiac measurements in neonates receiving acid suppression therapy during extracorporeal membrane oxygenation. Pharmacotherapy 2004;24(9):1130-1136.
52. Dodge WF, Jelliffe RW, Zwischenberger JB, et al. Population pharmacokinetic models: effect of explicit versus assumed constant serum concentration assay error patterns upon parameter values of gentamicin in infants on and off extracorporeal membrane oxygenation. Ther Drug Monit 1994;16(6):552-559.
53. Cohen P, Collart L, Prober CG, et al. Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. The Pediatric infectious disease journal 1990;9(8):562-566.
54. Moffett BS, Morris J, Galati M, et al. Population Pharmacokinetic Analysis of Gentamicin in Pediatric Extracorporeal Membrane Oxygenation. Ther Drug Monit 2018;40(5):581-588.
55. Southgate WM, DiPiro JT, Robertson AF. Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. Antimicrobial agents and chemotherapy 1989;33(6):817-819.
56. Munzenberger PJ, Massoud N. Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation. ASAIO Trans 1991;37(1):16-18.
57. Bhatt-Mehta V, Johnson CE, Schumacher RE. Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 1992;12(1):28-32.

58. Reiter PD, Ng J, Dobyns EL. Continuous hydromorphone for pain and sedation in mechanically ventilated infants and children. J Opioid Manag 2012;8(2):99-104.
59. Liviskie CJ, DeAvilla KM, Zeller BN, et al. Nicardipine for the Treatment of Neonatal Hypertension During Extracorporeal Membrane Oxygenation. Pediatric cardiology 2019;40(5):1041-1045.
60. McBride BF, White CM, Campbell M, et al. Nicardipine to control neonatal hypertension during extracorporeal membrane oxygen support. Ann Pharmacother 2003;37(5):667-670.
61. Tobias JD, Pietsch JB, Lynch A. Nicardipine to control mean arterial pressure during extracorporeal membrane oxygenation. Paediatric anaesthesia 1996;6(1):57-60.
62. Martin GR, Chauvin L, Short BL. Effects of hydralazine on cardiac performance in infants receiving extracorporeal membrane oxygenation. The Journal of pediatrics 1991;118(6):944-948.
63. Stone DM, Frattarelli DA, Karthikeyan S, et al. Altered prostaglandin E1 dosage during extracorporeal membrane oxygenation in a newborn with ductal-dependent congenital heart disease. Pediatric cardiology 2006;27(3):360-363.
64. Horwitz JR, Cofer BR, Warner BW, et al. A multicenter trial of 6-aminocaproic acid (Amicar) in the prevention of bleeding in infants on ECMO. J Pediatr Surg 1998;33(11):1610-1613.
65. Wilson JM, Bower LK, Fackler JC, et al. Aminocaproic acid decreases the incidence of intracranial hemorrhage and other hemorrhagic complications of ECMO. J Pediatr Surg 1993;28(4):536-540; discussion 540-531.
66. Downard CD, Betit P, Chang RW, et al. Impact of AMICAR on hemorrhagic complications of ECMO: a ten-year review. J Pediatr Surg 2003;38(8):1212-1216.
67. Pokorna P, Sima M, Vobruba V, et al. Phenobarbital pharmacokinetics in neonates and infants during extracorporeal membrane oxygenation. Perfusion 2018;33(1_suppl):80-86.
68. Elliott ES, Buck ML. Phenobarbital dosing and pharmacokinetics in a neonate receiving extracorporeal membrane oxygenation. Ann Pharmacother 1999;33(4):419-422.
69. Cies JJ, Moore WS, 2nd, Miller K, et al. Therapeutic drug monitoring of continuous-infusion acylovir for disseminated herpes simplex virus infection in a neonate receiving concurrent extracorporeal life support and continuous renal replacement therapy. Pharmacotherapy 2015;35(2):229-233.
70. Kendrick JG, Macready JJ, Kissoon N. Amiodarone treatment of junctional ectopic tachycardia in a neonate receiving extracorporeal membrane oxygenation. Ann Pharmacother 2006;40(10):1872-1875.
71. Wells TG, Fasules JW, Taylor BJ, et al. Pharmacokinetics and pharmacodynamics of bumetanide in neonates treated with extracorporeal membrane oxygenation. The Journal of pediatrics 1992;121(6):974-980.
72. Watt KM, Gonzalez D, Benjamin DK, Jr., et al. Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation. Antimicrobial agents and chemotherapy 2015;59(7):3935-3943.

73. Watt KM, Benjamin DK, Jr., Cheifetz IM, et al. Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. The Pediatric infectious disease journal 2012;31(10):1042-1047.
74. Minette MS, Ibsen LM. Survival of candida sepsis in extracorporeal membrane oxygenation. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 2005;6(6):709-711.
75. Watt KM, Cohen-Wolkowiez M, Williams DC, et al. Antifungal Extraction by the Extracorporeal Membrane Oxygenation Circuit. J Extra Corpor Technol 2017;49(3):150-159.
76. Cies JJ, Moore WS, 2nd, Dickerman MJ, et al. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support. Pharmacotherapy 2014;34(10):e175-179.
77. Cies JJ, Moore WS, 2nd, Conley SB, et al. Pharmacokinetics of Continuous Infusion Meropenem With Concurrent Extracorporeal Life Support and Continuous Renal Replacement Therapy: A Case Report. J Pediatr Pharmacol Ther 2016;21(1):92-97.
78. Di Nardo M, Cairoli S, Goffredo BM, et al. Therapeutic drug monitoring for meropenem after the extracorporeal membrane oxygenation circuit change in children: is it necessary? Minerva Anestesiol 2016;82(9):1018-1019.